✦ LIBER ✦

Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III

✍ Scribed by J. Cox-Brinkman; M. J. van Breemen; B. T. van Maldegem; L. Bour; W. E. Donker; C. E. M. Hollak; F. A. Wijburg; J. M. F. G. Aerts

Publisher: Springer
Year: 2008
Tongue: English
Weight: 344 KB
Volume: 31
Category: Article
ISSN: 0141-8955
DOI: 10.1007/s10545-008-0873-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved management of lysosomal glucosy

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

✍ John Marshall; Kerry Anne McEachern; Wei-Lien Chuang; Elizabeth Hutto; Craig S. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 367 KB

Acute lymphoblastic leukemia in a patien

Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy

✍ Aditi Ranade; Sorin Selegean; Gagangeet Sandhu; Violette Ghali; Vijay P. Shah 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

Higher rates of venous thromboembolism for Black-Americans are likely due to lower serum ## 25-hydroxyvitamin D levels To the editor: The recent paper on disparities of thromboembolism in the United States concluded that heritability may be important in the etiology of venous thromboembolism amon